Magazine Article | February 1, 2022

A Summary of Cell & Gene Therapies Market Outlook Report

Source: Life Science Leader

By Erin Harris, Editor-In-Chief, Cell & Gene
Follow Me On Twitter @ErinHarris_1

Even if your company isn’t developing and manufacturing cell and gene therapies (CGTs), you should be keenly aware of their almost limitless future therapeutic implications.

As such, I want to bring to your attention an important research report, Cell & Gene Therapies Market Outlook, released in Q3 2021 by Industry Standard Research (ISR). The report is based on data gathered from 101 respondents from North America, Europe, and Asia via a 15-minute web-based quantitative survey. This is the first edition of the report, and it was designed to provide support and direction for innovator companies with cell and/or gene therapies in their pipelines or portfolios as well as to CDMOs that are looking to win their manufacturing business.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader